Abstract
Background: Solid Dispersions (SDs) have been extensively used to increase the dissolution of poorly water-soluble drugs. However, there are few studies exploring SDs properties that must be considered during tablet development, like tabletability. Poorly water-soluble drugs with poor compression properties and high therapeutic doses, like gemfibrozil, are an additional challenge in the production of SDs-based tablets.
Objective: This study evaluates the applicability of SDs to improve both tabletability and dissolution rate of gemfibrozil. A SD-based tablet formulation was also proposed.
Methods: SDs were prepared by ball milling, using hydroxypropyl methylcellulose (HPMC) as a carrier, according to a 23 factorial design. The formulation variables were gemfibrozil:HPMC ratio, milling speed, and milling time. The response in the factorial analysis was the tensile strength of the compacted SDs. Dissolution rate and solid-state characterization of SDs were also performed.
Results: SDs showed simultaneous drug dissolution enhancement and improved tabletability when compared to corresponding physical mixtures and gemfibrozil. The main variable influencing drug dissolution and tabletability was the gemfibrozil:HPMC ratio. Tablets containing gemfibrozil- HPMC-SD (1:0.250 w/w) and croscarmellose sodium showed fast and complete drug release, while those containing the same SD and sodium starch glycolate exhibited poor drug release due to their prolonged disintegration time.
Conclusion: SDs proved to be effective for simultaneously improving tabletability and dissolution profile of gemfibrozil. Tablets containing gemfibrozil-HPMC-SD and croscarmellose sodium as disintegrating agent showed improved drug release and good mechanical strength, demonstrating the potential of HPMC-based SDs to simultaneously overcome the poor dissolution and tabletability properties of this drug.
Keywords: Gemfibrozil, solid dispersion, tabletability, tablet, drug dissolution, solubility.
Graphical Abstract
[http://dx.doi.org/10.1016/j.xphs.2015.10.008] [PMID: 26886314]
[http://dx.doi.org/10.2174/1381612825666190618121553] [PMID: 31258070]
[http://dx.doi.org/10.1208/s12249-013-9937-1] [PMID: 23430728]
[http://dx.doi.org/10.1016/j.carbpol.2013.08.046] [PMID: 24274533]
[http://dx.doi.org/10.1016/j.ejpb.2013.09.007] [PMID: 24056053]
[http://dx.doi.org/10.1016/j.ijpharm.2015.03.053] [PMID: 25827903]
[http://dx.doi.org/10.1016/j.jsps.2018.02.017] [PMID: 29991917]
[http://dx.doi.org/10.1016/j.ijpharm.2016.12.033] [PMID: 27988376]
[http://dx.doi.org/10.1080/17425247.2016.1198768] [PMID: 27321133]
[http://dx.doi.org/10.1163/016942410X525678]
[http://dx.doi.org/10.1016/j.xphs.2016.08.021] [PMID: 27769519]
[http://dx.doi.org/10.1111/j.2042-7158.2010.01025.x] [PMID: 21039537]
[http://dx.doi.org/10.1021/acs.bioconjchem.7b00646] [PMID: 29319295]
[http://dx.doi.org/10.1016/j.jconrel.2020.05.045] [PMID: 32479845]
[http://dx.doi.org/10.1016/S0928-0987(01)00095-1] [PMID: 11297896]
[http://dx.doi.org/10.1016/j.ejpb.2016.04.003] [PMID: 27063416]
[http://dx.doi.org/10.1016/j.ijpharm.2017.08.107] [PMID: 28859940]
[http://dx.doi.org/10.1016/j.powtec.2012.07.006]
[http://dx.doi.org/10.1016/j.ijpharm.2017.03.011] [PMID: 28284921]
[http://dx.doi.org/10.1208/s12248-015-9825-6] [PMID: 26338234]
[http://dx.doi.org/10.1016/j.polymer.2015.09.026]
[http://dx.doi.org/10.1016/j.ajps.2014.12.006]
[http://dx.doi.org/10.1016/j.colsurfa.2017.02.007]
[http://dx.doi.org/10.1016/j.ejps.2011.02.010] [PMID: 21382490]
[http://dx.doi.org/10.1023/A:1018967401000] [PMID: 7899240]